CFDs are complex instruments and come with a high risk of losing money rapidly due to leverage. 79.75% of retail investor accounts lose money when trading CFDs with this provider. You should consider whether you understand how CFDs work and whether you can afford to take the high risk of losing your money.
Open platformOpen platform

Immunovia Q3 net sales surge on PancreaSure uptake

By Reuters News


Overview

  • Sweden diagnostic firm's Q3 net sales rose sharply yr/yr, driven by PancreaSure test sales

  • Operating loss narrowed compared to Q3 2025

  • Company announced SEK 63 mln rights issue to fund US commercialization and clinical studies


Outlook

  • Company awaits Medicare coverage decision for PancreaSure, which could expand future revenue

  • Immunovia plans to use rights issue proceeds to fund US commercialization and clinical studies

  • Company expects recent clinical results to support commercial adoption and reimbursement efforts


Result Drivers

  • TEST ADOPTION - Co said increased uptake of PancreaSure test and addition of high-risk surveillance centers drove Q3 sales, per CEO Jeff Borcherding

  • LOWER STUDY COSTS - Co said reduced spending on clinical studies lowered operating cash burn in Q3


Company press release:


Key Details

Metric

Beat/Miss

Actual

Consensus Estimate

Q3 Adjusted Loss Per Share

SEK 0.03

Q3 Adjusted Free Cash Flow

-SEK 14.90 mln


Analyst Coverage

  • Wall Street's median 12-month price target for Immunovia AB (publ) is SEK0.43, about 758.3% above its October 30 closing price of SEK0.05


Reuters Recommended Reads

  • Oct 30 - Sweden's Invisio Q3 revenue misses estimates

  • Oct 30 - Canada's Aurinia Q3 revenue rises 14% on LUPKYNIS sales

  • Oct 30 - AstraZeneca CEO strikes bullish tone on pipeline as stock rallies


For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact reuters.support@thomsonreuters.com.


(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)

Capital.com is an execution-only brokerage platform and the content provided on the Capital.com website is intended for informational purposes only and should not be regarded as an offer to sell or a solicitation of an offer to buy the products or securities to which it applies. No representation or warranty is given as to the accuracy or completeness of the information provided.

The information provided does not constitute investment advice nor take into account the individual financial circumstances or objectives of any investor. Any information that may be provided relating to past performance is not a reliable indicator of future results or performance.

To the extent permitted by law, in no event shall Capital.com (or any affiliate or employee) have any liability for any loss arising from the use of the information provided. Any person acting on the information does so entirely at their own risk.

Any information which could be construed as “investment research” has not been prepared in accordance with legal requirements designed to promote the independence of investment research and as such is considered to be a marketing communication.